Capilla Javier, Clemons Karl V, Liu Min, Levine Hillel B, Stevens David A
California Inst. for Med. Res., San Jose, CA, United States.
Vaccine. 2009 Jun 2;27(27):3662-8. doi: 10.1016/j.vaccine.2009.03.030. Epub 2009 Apr 2.
Disseminated coccidioidomycosis is a life-threatening infection. In these studies, we examined protection against systemic murine coccidioidomycosis by vaccination with heat-killed Saccharomyces cerevisiae (HKY). CD-1 mice received HKY subcutaneously or by oral gavage with or without adjuvants once weekly beginning 3 or 4 weeks prior to infection; oral live Saccharomyces was also studied. All HKY sc regimens were equivalent, prolonging survival (P<or=0.005) and reducing fungal burden versus controls. Oral live Saccharomyces, but not HKY, prolonged survival (P=0.03), but did not reduce fungal burden. Survival of mice given HKY was equivalent to vaccination with formalin-killed spherules, but inferior in reduction of fungal burden. HKY was superior to a successful recombinant vaccine, PRA plus adjuvant. This novel heterologous protection afforded by HKY vaccination offers a new approach to a vaccine against coccidioidomycosis.
播散性球孢子菌病是一种危及生命的感染。在这些研究中，我们检测了用热灭活的酿酒酵母（HKY）进行疫苗接种对系统性小鼠球孢子菌病的保护作用。CD-1小鼠在感染前3或4周开始，每周一次皮下或通过口服给予HKY，有无佐剂均可；也对口服活酿酒酵母进行了研究。所有HKY皮下给药方案效果相当，与对照组相比，可延长生存期（P≤0.005）并减轻真菌负荷。口服活酿酒酵母可延长生存期（P=0.03），但不能减轻真菌负荷，而HKY则无此作用。给予HKY的小鼠生存期与用福尔马林灭活的球形体疫苗接种相当，但在减轻真菌负荷方面较差。HKY优于一种成功的重组疫苗PRA加佐剂。HKY疫苗接种所提供的这种新型异源保护为抗球孢子菌病疫苗提供了一种新方法。
